Does Rallies show 13F holders for CGON?

Yes. Rallies tracks hedge fund and 13F ownership data for CGON, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CGON research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CGON. It does not provide personalized investment advice.

CGON (CG Oncology, Inc. Common stock) Stock Analysis - Hedge Fund Holdings

CG Oncology, Inc. Common stock (CGON) is a publicly traded Healthcare sector company. As of May 20, 2026, CGON trades at $64.79 with a market cap of $5.55B and a P/E ratio of -27.62. CGON moved +2.37% today. Year to date, CGON is +61.74%; over the trailing twelve months it is +143.82%. Its 52-week range spans $14.80 to $75.50. Analyst consensus is strong buy with an average price target of $89.47. Rallies surfaces CGON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CGON stock?

Hedge funds tracked by Rallies that own CGON include Orbimed Advisors, Farallon Capital, Mangrove Partners, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CG Oncology, Inc. Common stock.

CGON Key Metrics

Key financial metrics for CGON
Metric	Value
Price	$64.79
Market Cap	$5.55B
P/E Ratio	-27.62
EPS	$-2.33
Dividend Yield	0.00%
52-Week High	$75.50
52-Week Low	$14.80
Volume	666.18K
Avg Volume	0
Revenue (TTM)	$5.07M
Net Income	$-186.75M
Gross Margin	0.00%

Top Hedge Funds Holding CGON

Orbimed Advisors holds 948.27K shares of CGON, changed -37.47% as of Mar 31, 2026.
Farallon Capital holds 674.00K shares of CGON, changed +8325.00% as of Mar 31, 2026.
Mangrove Partners holds 671.69K shares of CGON, changed +21.00% as of Sep 30, 2025.
Centerbook Partners holds 69.22K shares of CGON, changed -82.49% as of Dec 31, 2025.

Latest CGON News

CG Oncology rises as traders price in near-term Phase 3 PIVOT-006 data and target hikes — Apr 30, 2026
CG Oncology dips as insider-sale filings hit tape after recent rally — Apr 22, 2026
CG Oncology rises as accelerated Phase 3 PIVOT-006 readout outlook supports shares — Apr 21, 2026
CG Oncology slips as investors de-risk ahead of May 7 earnings catalyst — Apr 20, 2026
CG Oncology jumps as PIVOT-006 Phase 3 catalyst nears and analysts turn louder — Apr 19, 2026

Recent CGON Insider Trades

Mulay James sold 15.60K (~$1.14M) on Apr 17, 2026.
Mulay James sold 654 (~$41.53K) on Mar 16, 2026.
Mulay James sold 1.31K (~$83.19K) on Mar 16, 2026.

CGON Analyst Consensus

13 analysts cover CGON: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.47.

Common questions about CGON

Who owns CGON stock?: Hedge funds tracked by Rallies that own CGON include Orbimed Advisors, Farallon Capital, Mangrove Partners, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CG Oncology, Inc. Common stock.
Does Rallies show 13F holders for CGON?: Yes. Rallies tracks hedge fund and 13F ownership data for CGON, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CGON research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CGON. It does not provide personalized investment advice.